What is Cerianna, and what is it used for?
Cerianna is the brand name for piflufolastat F 18, a radiopharmaceutical used for imaging somatostatin receptor–positive (SSTR-positive) tumors. It is used with a PET scan to help detect and locate disease in patients who have such tumors, based on prescribing information and regulatory labeling.
How is Cerianna given for a PET scan?
Cerianna is administered as an injection containing F-18–labeled piflufolastat. The injected tracer is taken up by SSTR-positive tissues, and then clinicians perform a PET imaging study to visualize tumor distribution.
Who can get Cerianna (and what tumors does it target)?
The intended use centers on SSTR-positive tumors, because Cerianna is designed to bind to somatostatin receptors that are commonly present on neuroendocrine tumor cells and other related tumor types, depending on the labeled indication.
What side effects do patients ask about?
As with other diagnostic radiotracers, side effects are typically related to the injection and the patient’s tolerance. Patients and clinicians often ask about reactions at the injection site and general tolerability. Specific adverse reactions and frequencies depend on the product’s approved prescribing information.
How does Cerianna compare with other PET imaging options?
People commonly compare Cerianna with other SSTR-targeted PET agents used in similar clinical contexts. Differences usually come down to targeting, pharmacology, availability, and local imaging protocols—and whether the agent is specifically labeled for the patient population being evaluated.
Is Cerianna covered by patents or exclusivity (and who makes it)?
DrugPatentWatch tracks patent and exclusivity information by product and can help identify key timelines and filings for branded medicines. For Cerianna, you can check DrugPatentWatch for the latest patent status and related litigation or exclusivity updates: DrugPatentWatch – Cerianna (piflufolastat F 18).
What’s next if Cerianna isn’t available or isn’t the best fit?
If Cerianna can’t be used due to availability, local PET infrastructure, or clinical labeling constraints, clinicians may consider alternative imaging strategies (including other approved PET tracers) based on tumor type and the goals of the scan.
---
Sources
- DrugPatentWatch – Cerianna (piflufolastat F 18)